Premium
DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (POLLUX)
Author(s) -
Bahlis N.J.,
Moreau P.,
Nahi H.,
Plesner T.,
Goldschmidt H.,
Suzuki K.,
Orlowski R.Z.,
Rabin N.,
Leiba M.,
Oriol A.,
Chari A.,
San Miguel J.,
Richardson P.G.,
Usmani S.,
O'Rourke L.,
Wu K.,
Casneuf T.,
Chiu C.,
Qin X.,
Dimopoulos M.A.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_153
Subject(s) - lenalidomide , daratumumab , medicine , dexamethasone , multiple myeloma , oncology , refractory (planetary science) , minimal residual disease , gastroenterology , bone marrow , physics , astrobiology